

Clinical Trial Protocol

Iranian Registry of Clinical Trials

30 May 2026

Investigating the prophylactic effect of antiglaucoma drugs on eye pressure in patients undergoing intravitreal injection of bevacizumab

Protocol summary

Study aim

Determining the prophylactic effect of antiglaucoma drugs on eye pressure in patients undergoing intravitreal injection of bevacizumab

Design

A controlled, single-blind, randomized, phase 3 clinical trial on 108 patients. R statistical software version 4.0.2 was used for randomization

Settings and conduct

The study population in this research is all patients who are candidates for intravitreal injection of bevacizumab referred to Al-Zahra Ophthalmology Hospital. In this research, single blinding method is used. So that the person responsible for recording the results (eye resident) will not be aware of the desired intervention.

Participants/Inclusion and exclusion criteria

Inclusion criteria include: 1- Age more than 18 years 2- Informed and free consent to participate in the study 3- Patients who will have the first intra-boasizomat injection. Exclusion criteria also include: 1- History of retinal surgery 2- Rupture of the posterior capsule 3- High eye pressure or glaucoma 4- Use of topical medication 5- Active intraocular inflammation 6- Eye pathologies 7- Withdrawal from the study during research for any reason

Intervention groups

Patients were randomly divided into 4 groups, group A: topical timolol 0.5% (2 drops with a time interval of 10 minutes, 60-90 minutes before intervention), group B: combination of dorzolamide hydrochloride 2% and timolol maleate 0.5% and brand name Xylomol® (2 drops with an interval of 10 minutes, 60-90 minutes before the intervention), group C: oral acetazolamide 500 mg (90-120 minutes before the intervention), group D: placebo drop group (one drop artificial tears, which will be administered 2 drops with an interval of 10 minutes, 60-90 minutes before the intervention) will be divided

Main outcome variables

Intraocular pressure

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20230330057787N1**

Registration date: **2023-09-04, 1402/06/13**

Registration timing: **prospective**

Last update: **2023-09-04, 1402/06/13**

Update count: **0**

Registration date

2023-09-04, 1402/06/13

Registrant information

Name

fatemeh asli

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 54 3222 9705

Email address

fateme813@yahoo.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-09-23, 1402/07/01

Expected recruitment end date

2024-02-20, 1402/12/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Investigating the prophylactic effect of antiglaucoma drugs on eye pressure in patients undergoing intravitreal injection of bevacizumab

Public title

effect of anti-glaucoma agents on intra ocular pressure Spikes after intravitreal bevacizumab injection in patients

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

1- Age more than 18 years 2- Informed and free consent to participate in the study 3- Patients who will have the first intra-boasizomat injection.

Exclusion criteria:

1- History of retinal surgery. 2- Rupture of the posterior capsule 3- High eye pressure or glaucoma 4- Use of topical medication (such as IOP-lowering medications and corticosteroids) 5- Active intraocular inflammation 6- Eye pathologies such as pterygium or corneal opacities that can affect the evaluation of study variables 7- Withdrawal from the study during research for any reason

Age

From **18 years** old

Gender

Both

Phase

3

Groups that have been masked

- Outcome assessor

Sample size

Target sample size: **108**

Randomization (investigator's opinion)

Randomized

Randomization description

Random assignment of patients to 5 groups is done by permuted stratified randomization method. In this way, first, eligible referring patients are classified according to age and gender in the order of arrival. Then they are randomly assigned to the desired group. These permutations were created using statistical software R version 4.0.2

Blinding (investigator's opinion)

Single blinded

Blinding description

In this research, single blinding method is used. So that the person responsible for recording the results (eye resident) will not be aware of the intended intervention.

Placebo

Used

Assignment

Other

Other design features

A controlled, single-blind, randomized, phase 3 clinical trial on 108 patients. R statistical software version 4.0.2 was used for randomization

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Zahedan University of Medical Sciences

Street address

Zahedan - Doctor Hasabi Square - Medical Sciences Campus

City

zahedan

Province

Sistan-va-Balouchestan

Postal code

9816743463

Approval date

2023-03-01, 1401/12/10

Ethics committee reference number

IR.ZAUMS.REC.1401.433

Health conditions studied

1

Description of health condition studied

Eye pressure of patients undergoing intravitreal injection of bevacizumab

ICD-10 code

H40.6

ICD-10 code description

Glaucoma secondary to drugs

Primary outcomes

1

Description

Intraocular pressure

Timepoint

The beginning of the study / one minute after injection / 30 minutes after injection / 24 hours after injection

Method of measurement

At the beginning of the study, 30 minutes after the injection and 24 hours after the injection, the intraocular pressure is measured with a Goldman tonometer and one minute after the injection with Tonopen.

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: In the first group, 0.5% topical timolol drops (2 drops with a 10-minute interval, 60-90 minutes before the intervention) are prescribed.

Category

Treatment - Drugs

2**Description**

Intervention group: In the second group, the combination of dorzolamide hydrochloride 2% and timolol maleate 0.5% with the brand Xylomol® (2 drops with a time interval of 10 minutes, 60-90 minutes before the intervention) is prescribed.

Category

Treatment - Drugs

3**Description**

Intervention group: In the third group, oral acetazolamide 500 mg is administered (90-120 minutes before the intervention).

Category

Treatment - Drugs

4**Description**

Control group: In this group, placebo drops (an artificial tear drop, 2 drops with a time interval of 10 minutes, 60-90 minutes before the intervention) are prescribed.

Category

Placebo

Recruitment centers**1****Recruitment center****Name of recruitment center**

Al-Zahra Ophthalmology Hospital

Full name of responsible person

Mr. Dr. Mohammad Erish

Street address

Zahedan Motahari Blvd. has not reached Khatam Square of Al-Zahra Ophthalmology Hospital

City

zahedan

Province

Sistan-va-Balouchestan

Postal code

9816737789

Phone

+98 54 3321 9915

Fax

+98 54 3323 3550

Email

ALzahra_eyecenter@yahoo.com

Web page address

http://eye.zaums.ac.ir

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Zahedan University of Medical Sciences

Full name of responsible person

Dr. Nur Mohammad Bakhshani

Street address

Zahedan Square, Dr. Hasabi Campus, University of Medical Sciences

City

zahedan

Province

Sistan-va-Balouchestan

Postal code

9816743463

Phone

+98 54 3337 2151

Fax

+98 54 3329 5771

Email

info@zaums.ac.ir

Web page address

https://zaums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Zahedan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Zahedan University of Medical Sciences

Full name of responsible person

Mr. Dr. Mohammad Erish

Position

Assistant Professor

Latest degree

Subspecialist

Other areas of specialty/work

Ophthalmology

Street address

Zahedan Motahari Blvd. has not reached Khatam Square of Al-Zahra Ophthalmology Hospital

City

zahedan

Province

Sistan-va-Balouchestan

Postal code

۹۸۱۶۷۳۷۷۸۹

Phone

+98 54 3321 9915

Fax

+98 54 3323 3550

Email

ALzahra_eyecenter@yahoo.com

Web page address

<http://eye.zaums.ac.ir>

Person responsible for scientific inquiries

Contact

Name of organization / entity

Zahedan University of Medical Sciences

Full name of responsible person

Mr. Dr. Mohammad Erish

Position

Associate professor

Latest degree

Subspecialist

Other areas of specialty/work

Ophthalmology

Street address

Zahedan Motahari Blvd. has not reached Khatam

Square of Al-Zahra Ophthalmology Hospital

City

zahedan

Province

Sistan-va-Balouchestan

Postal code

9816737789

Phone

+98 54 3321 9915

Fax

+98 54 3323 3550

Email

ALzahra_eyecenter@yahoo.com

Web page address

<https://eye.zaums.ac.ir>

Person responsible for updating data

Contact

Name of organization / entity

Zahedan University of Medical Sciences

Full name of responsible person

Mr. Dr. Mohammad Erish

Position

Associate professor

Latest degree

Subspecialist

Other areas of specialty/work

Ophthalmology

Street address

Zahedan Motahari Blvd. has not reached Khatam

Square of Al-Zahra Ophthalmology Hospital

City

zahedan

Province

Sistan-va-Balouchestan

Postal code

9816737789

Phone

+98 54 3321 9915

Fax

+98 54 3323 3550

Email

ALzahra_eyecenter@yahoo.com

Web page address

<https://eye.zaums.ac.ir>

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available